Biosyt Ltd. (02315) announced an anticipated loss of approximately 4.47 million yuan to 5.47 million yuan (RMB) for the six months ending June 30, 2024. Compared with the financial data for the same period last year, the anticipated loss will decrease by about 1.351 million yuan to 1.451 million yuan, a year-on-year decrease of about 71.2% to 76.4%.
It is expected that the group's revenue in the first half of the year will be about 0.406 billion yuan to 0.416 billion yuan. Compared with the financial data for the same period last year, it will increase by about 7.87 million yuan to 8.87 million yuan, a year-on-year increase of about 24.1% to 27.1%.
It is expected that the group's R&D expenses in the first half of the year will be about 0.157 billion yuan to 0.167 billion yuan. Compared with the financial data for the same period last year, it will decrease by about 81.3 million yuan to 91.3 million yuan, a year-on-year decrease of about 32.8% to 36.8%.
The main reason for the expected increase in performance this period is that the "Thousand Mice, Ten Thousand Antibodies" plan has completed its phase and the company has built a spot-shelf containing over 0.4 million human antibody sequences for large-scale external antibody molecular authorization cooperation. The high-margin antibody authorization business has become one of the core driving forces for the company's rapid growth. In the first half of 2024, the number of external cooperation development/authorization/transfer agreements and the revenue from antibody authorization business for non-core products maintained a high growth rate.